The Maharashtra Food and Drug Administration seized 20,085 litres of edible oil valued at Rs 50.27 lakh from an Avenue Supermarts Limited facility in Ambi village, Maval taluka, Pune district, after suspecting the stock of being substandard and misbranded under the Food Safety and Standards Act.
The raid was conducted on November 17 by the FDA’s Pune Division-10 as part of the ‘Safe Food, Safe Maharashtra’ campaign. The facility is located at Gat No. 113, Shed No. 1, in Ambi village. The action brought a large retail supply facility under regulatory inspection rather than focusing only on individual shops or consumer-facing outlets.
According to the FDA, officers collected nine samples of edible oil products during the inspection and sent them to a laboratory for analysis. The samples covered refined sunflower oil, physically refined rice bran oil, kachi ghani mustard oil, and cold-pressed mustard and groundnut oils.
The products were available in different packaging formats, including pouches, bottles and jars. The brands from which samples were collected included Aadhar, Fortune, Patanjali and Saffola. The FDA has not declared the products unsafe on the basis of the seizure alone; the laboratory reports will determine whether the stock breached applicable food-safety or labelling standards.
The inspection was carried out under the guidance of Maharashtra FDA Joint Commissioner (Vigilance) Priti Tipre and Pune Division Joint Commissioner (Food) Shrikant Karakale. Food Safety Officer Balaji Shinde gathered the intelligence inputs that led to the operation.
A team led by Assistant Commissioner D. S. Salunkhe, along with Food Safety Officer A. B. Bhise and Food Safety Officer S. S. Hake, conducted the inspection and seizure. The scale of the stock means that the laboratory findings will be relevant not only to the facility but also to the regulatory oversight of packaged edible oils moving through organised retail supply chains in the Pune region.
Joint Commissioner Karakale said the seized samples had been sent for laboratory testing and that further legal action would be initiated after the reports were received. Until those reports are available, the FDA’s action remains a seizure of suspected substandard and misbranded stock rather than a final finding against the products or brands named in the inspection.


